{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:05:38Z","timestamp":1762542338545},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T00:00:00Z","timestamp":1419033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00347-014-3137-6","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T02:23:20Z","timestamp":1418955800000},"page":"435-443","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapiewechsel von Ranibizumab zu Aflibercept bei rezidivierender oder persistierender exsudativer altersbedingter Makuladegeneration"],"prefix":"10.1007","volume":"112","author":[{"given":"M.","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Heimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Book","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dietzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zeimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gutfleisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,20]]},"reference":[{"key":"3137_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","volume":"156","author":"Bakall","year":"2013","unstructured":"Bakall B, Folk JC, Boldt HC et al (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15\u201322","journal-title":"Am J Ophthalmol"},{"key":"3137_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","volume":"96","author":"Binder","year":"2012","unstructured":"Binder S (2012) Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96:1\u20132","journal-title":"Br J Ophthalmol"},{"key":"3137_CR3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"Catt","year":"2011","unstructured":"Catt Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897\u20131908","journal-title":"N Engl J Med"},{"key":"3137_CR4","first-page":"61501","volume":"18","author":"Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 18:61501\u201361509","journal-title":"Lancet"},{"key":"3137_CR5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"Chakravarthy","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399\u20131411","journal-title":"Ophthalmology"},{"key":"3137_CR6","first-page":"12234","volume":"2","author":"Clemens","year":"2013","unstructured":"Clemens CR, Bastian N, Alten F et al (2013) Prediction of retinal pigment epithelial tear in serous vascularized pigment epithelium detachment. Acta Ophthalmol 2:12234","journal-title":"Acta Ophthalmol"},{"key":"3137_CR7","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bjophthalmol-2011-301415","volume":"96","author":"Clemens","year":"2012","unstructured":"Clemens CR, Krohne TU, Charbel Issa P et al (2012) High-resolution optical coherence tomography of subpigment epithelial structures in patients with pigment epithelium detachment secondary to age-related macular degeneration. Br J Ophthalmol 96:1088\u20131091","journal-title":"Br J Ophthalmol"},{"key":"3137_CR8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00347-013-2788-z","volume":"110","author":"Deutsche","year":"2013","unstructured":"Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband Der Augen\u00e4rzte Deutschlands (2013) Stellungnahme: Die Anti-VEGF-Therapie bei der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration: Therapeutische Strategien. Ophthalmologe 110:191\u2013198","journal-title":"Ophthalmologe"},{"key":"3137_CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21\u201323","journal-title":"Br J Ophthalmol"},{"key":"3137_CR10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"29","author":"Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle CB et al (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723\u2013731","journal-title":"Retina"},{"key":"3137_CR11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/bjo.2011.204685","volume":"96","author":"Gasperini","year":"2012","unstructured":"Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14\u201320","journal-title":"Br J Ophthalmol"},{"key":"3137_CR12","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"3137_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2013.02.009","volume":"156","author":"Ho","year":"2013","unstructured":"Ho VY, Yeh S, Olsen TW et al (2013) Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 156:23\u201328","journal-title":"Am J Ophthalmol"},{"key":"3137_CR14","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S et al (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605\u20131612","journal-title":"Retina"},{"key":"3137_CR15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00347-010-2143-6","volume":"107","author":"Lommatzsch","year":"2010","unstructured":"Lommatzsch A (2010) Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options. Ophthalmologe 107:1115\u20131122","journal-title":"Ophthalmologe"},{"key":"3137_CR16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00347-010-2221-9","volume":"108","author":"Lommatzsch","year":"2011","unstructured":"Lommatzsch A, Heimes B, Gutfleisch M et al (2011) Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy. Ophthalmologe 108:244\u2013251","journal-title":"Ophthalmologe"},{"key":"3137_CR17","doi-asserted-by":"crossref","unstructured":"Lommatzsch A, Heimes B, Gutfleisch M et al (2009) Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond) 23:2163\u20132168","DOI":"10.1038\/eye.2008.425"},{"key":"3137_CR18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1055\/s-2008-1027454","volume":"225","author":"Lommatzsch","year":"2008","unstructured":"Lommatzsch AP, Heimes B, Gutfleisch M et al (2008) Treatment of vascularised serous pigment epithelium detachment in AMD \u2013 observations after changing the intravitreal agent due to lack of response. Klin Monatsbl Augenheilkd 225:874\u2013879","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"3137_CR19","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"},{"key":"3137_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185","journal-title":"Angiogenesis"},{"key":"3137_CR21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/eye.2013.31","volume":"27","author":"Patel","year":"2013","unstructured":"Patel KH, Chow CC, Rathod R et al (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 27:663\u2013667 (quiz 668)","journal-title":"Eye"},{"key":"3137_CR22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0032-1328113","volume":"230","author":"Redaktionskommittee","year":"2013","unstructured":"Redaktionskommittee, Pauleikhoff D, Bertram B et al (2013) Die Anti-VEGF-Therapie bei der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration: Therapeutische Strategien Stand Dezember 2012. Klin Monatsbl Augenheilkd 230:170\u2013177","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"3137_CR23","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292\u20132299","journal-title":"Ophthalmology"},{"key":"3137_CR24","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199\u20132205","journal-title":"Ophthalmology"},{"key":"3137_CR25","first-page":"317","volume":"Today","author":"Verner-Cole","year":"2012","unstructured":"Verner-Cole EA, Davis SJ, Lauer AK (2012) Aflibercept for the treatment of neovascular age-related macular degeneration. Drugs Today (Barc) 48:317\u2013329","journal-title":"Drugs"},{"key":"3137_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ajo.2013.03.030","volume":"156","author":"Yonekawa","year":"2013","unstructured":"Yonekawa Y, Andreoli C, Miller JB et al (2013) Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 156:29\u201335","journal-title":"Am J Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-014-3137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-014-3137-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-014-3137-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:51:57Z","timestamp":1559037117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-014-3137-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,20]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["3137"],"URL":"https:\/\/doi.org\/10.1007\/s00347-014-3137-6","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,20]]}}}